Abstract: It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).

Abstract: The fixing device having a long durability life includes a first member, a heater, and a second member, the heater including a base material, an intermediate layer on the base material, and a surface layer on the intermediate layer, which includes a diamond-like carbon film, the base material containing at least one compound selected from the group consisting of aluminum nitride, aluminum oxide, and silicon nitride, and the intermediate layer has a ratio of [(Si)+(C)]/A of 0.8 or more, and a ratio of (Si)/(C) of more than 1.

Abstract: The fixing device having a long durability life includes a first member, a heater, and a second member, the heater including a base material, an intermediate layer on the base material, and a surface layer on the intermediate layer, which includes a diamond-like carbon film, the base material containing at least one compound selected from the group consisting of aluminum nitride, aluminum oxide, and silicon nitride, and the intermediate layer has a ratio of [(Si)+(C)]/A of 0.8 or more, and a ratio of (Si)/(C) of more than 1.

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: It is an object to provide effective means for preventing and/or treating fulminant acute pneumonia. Provided are a pharmaceutical agent or pharmaceutical composition to be used for preventing and/or treating fulminant acute pneumonia, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing intra-alveolar neutrophil aggregation, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), an agent for suppressing pulmonary neutrophil infiltration, containing a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody), and a method of preventing and/or treating fulminant acute pneumonia, including administering a CD69 antagonist, such as an antibody that specifically recognizes CD69 (anti-CD69 antibody).

Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: Provided is an endless belt-shaped electrophotographic member having a superior durability. The member comprises an endless belt-shaped substrate and a surface layer, the surface layer comprising an ionizing radiation crosslinked product of a tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer (PFA), the surface layer is formed by irradiation of electron beam to a resin layer, the resin layer comprising the PFA, the surface layer has a universal hardness HU at 200° C. of 18 N/mm2?HU?40 N/mm2, and when a degree of orientation of the PFA in the resin layer in a direction orthogonal to the circumferential direction of the substrate is defined as Ri, and a degree of orientation of the crosslinked PFA in the surface layer in the direction orthogonal to the circumferential direction of the substrate is defined as Rf, Ri and Rf satisfy a relationship represented by expression (1): Ri×0.8?Rf?Ri??(1).

Abstract: The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

Abstract: An image forming apparatus has an image forming portion, and a fixing portion including a first rotatable member and a second rotatable member that form a nip, and a detecting portion configured to detect a temperature of the first rotatable member. An acquiring portion acquires a rotation time of the first rotatable member, and a notifying portion provides a notification prompting exchange of the first rotatable member on the basis of an accumulated value of the rotation time of the first rotatable member acquired by the acquiring portion, the rotation time being subjected to weighting on the basis of the temperature of the first rotatable member detected by the detecting portion.

Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is an endless belt-shaped electrophotographic member having a superior durability. The member comprises an endless belt-shaped substrate and a surface layer, the surface layer comprising an ionizing radiation crosslinked product of a tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer (PFA), the surface layer is formed by irradiation of electron beam to a resin layer, the resin layer comprising the PFA, the surface layer has a universal hardness HU at 200° C. of 18 N/mm2?HU?40 N/mm2, and when a degree of orientation of the PFA in the resin layer in a direction orthogonal to the circumferential direction of the substrate is defined as Ri, and a degree of orientation of the crosslinked PFA in the surface layer in the direction orthogonal to the circumferential direction of the substrate is defined as Rf, Ri and Rf satisfy a relationship represented by expression (1): Ri×0.8?Rf?Ri??(1).

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: A fixing member is provided, including a release layer containing a tetrafluoroethylene-perfluoroalkyl vinyl ether copolymer (PFA), wherein a content of the perfluoroalkyl vinyl ether (PAVE) based on all PFAs in the release layer is 3.0 mol % or more and 5.8 mol % or less, and an elastic layer having an indentation elastic modulus EITs at a surface thereof and an indentation elastic modulus EITc at a position in a depth of 50 ?m from the surface, EITs and EITc being measured at a temperature of 150° C., and EITs is larger than EITc and EITc being 17 MPa or more and 24 MPa or less.

Abstract: An elastic layer includes a needle-shaped filler and a void and has a porosity of 20 vol % or more and 60 vol % or less. The elastic layer contains a first area and a second area. The first area extends from a surface of the elastic layer opposite to a surface facing the mandrel toward the mandrel and has a thickness of 30% of the thickness of the elastic layer. The second area is a central area in a thickness direction of the elastic layer and has a thickness of 40% of the thickness of the elastic layer. The needle-shaped filler in the second area has an orientation degree of 50% or lower. The needle-shaped filler in the first area has an orientation degree higher than that of the needle-shaped filler in the second area.

Abstract: A heater usable with an image heating apparatus includes first and second terminals, a connector, and an endless heating belt. At least one first contact is provided on a substrate and connectable with the first terminal through the connector, and second contacts are provided on the substrate and connectable with the second terminal through the connector. The heater also includes electrodes, including a first electrode connected with the first contact and second electrodes connected with the second contacts, the first electrodes and the second electrodes being arranged alternately with predetermined gaps in a longitudinal direction of the substrate. A plurality of heat generating portions are provided between adjacent electrodes so as to connect between adjacent electrodes, and are capable of generating heat by the electric power supply between adjacent electrodes. The first contact and the second contacts are all disposed in one longitudinal end portion side of the substrate.